Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Laughing Water Capital Matthew Sweeney | “Theravance Biopharma was introduced in our Q1'26 letter. Following the failure of a Phase III drug trial the company was a special situation tied to a drug-related royalty stream, and the company announced that a strategic review committee was considering all options to create value for shareholders. I believed the most likely outcome would be a sale of the company at a price somewhere between $17 and $25 at some point in the next few months. News of a sale came in near quarter end at the low end of my expected range. The Theravance buyout came at the bottom end of my fair value estimate range.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Summers Value Fund Andrew Summers | “The fund initiated a position in Theravance after its primary development asset failed, triggering a major restructuring and transition to a highly profitable royalty model. The core value of the business is supported by long-duration COPD therapy royalties, significant tax assets, and substantial cash reserves. Additionally, a strategic review committee is currently exploring options that could lead to an outright sale of the company.” | BULL | Q1 2026 Apr 25, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
